Mahana Therapeutics rallies $61m Series B

Mahana Therapeutics, a developer of prescription digital therapeutics, has secured $61 million in Series B financing.

Mahana Therapeutics, a developer of prescription digital therapeutics, has secured $61 million in Series B financing. JAZZ Venture Partners and Gurnet Point Capital led the round with significant participation from Main Street Advisors, KKCG and Lux Capital.

Source: Press Release